<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01052012</url>
  </required_header>
  <id_info>
    <org_study_id>C803-025</org_study_id>
    <nct_id>NCT01052012</nct_id>
  </id_info>
  <brief_title>Bupivacaine Effectiveness and Safety in SABER™ Trial</brief_title>
  <acronym>BESST</acronym>
  <official_title>Bupivacaine Effectiveness and Safety in SABER™ Trial (BESST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Durect</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nycomed</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospira, now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Durect</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a research study testing SABER™-Bupivacaine (an experimental pain-relieving
      medication). SABER™-Bupivacaine is designed to continuously deliver bupivacaine, a common
      local anesthetic, for a few days in order to treat local post-surgical pain.

      The purpose of this study is to investigate safety (side effects) associated with the use of
      SABER™-Bupivacaine and how well it works in reducing pain and opioid-related side effects
      following various kinds of abdominal surgeries.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain intensity on movement</measure>
    <time_frame>0 to 3 days post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Supplemental opioid use</measure>
    <time_frame>0 to 3 days post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean pain intensity on movement</measure>
    <time_frame>0 to 2 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean total morphine-equivalent dose</measure>
    <time_frame>0 to 2 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who have evidence of a wound infection</measure>
    <time_frame>0 to 14 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-first use of opioid rescue medication</measure>
    <time_frame>0 to 14 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of opioid-related side effects</measure>
    <time_frame>0 to 30 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean pain intensity at rest during</measure>
    <time_frame>0 to 3 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean pain intensity at rest</measure>
    <time_frame>0 to 2 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean scores on the Recovery Index</measure>
    <time_frame>0 to 7 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Post-Anesthetic Discharge Scoring System</measure>
    <time_frame>0 to 14 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment satisfaction</measure>
    <time_frame>0 to 14 days post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">305</enrollment>
  <condition>Postoperative Pain</condition>
  <condition>Abdominal Surgery</condition>
  <arm_group>
    <arm_group_label>Active: SABER™-Bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SABER™-Bupivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator: Bupivacaine HCl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivacaine HCl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo: SABER™-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>SABER™-Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SABER™-Bupivacaine</intervention_name>
    <description>Injectable Extended Release Solution; SABER™-Bupivacaine /Once</description>
    <arm_group_label>Active: SABER™-Bupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine HCl</intervention_name>
    <description>Injectable Solution; Bupivacaine HCl /Once</description>
    <arm_group_label>Comparator: Bupivacaine HCl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SABER™-Placebo</intervention_name>
    <description>Injectable Solution; SABER™-Placebo/Once</description>
    <arm_group_label>Placebo: SABER™-Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be able to read and understand the consent form, provide written
             consent, complete trial-related procedures, and communicate with the trial staff

          -  Males and females, 18 years of age and older scheduled to undergo elective general
             abdominal surgery

          -  Patients must be healthy or have only mild systemic diseasePatients must be healthy or
             have only mild systemic disease

          -  BMI &lt; 45

          -  Patients must have ECG wave form within normal limits

          -  Female and male patients must agree to use medically acceptable method of
             contraception throughout the entire trial period and for 1 week after the trial
             participation is completed

        Exclusion Criteria:

          -  Patients who are pregnant or lactating

          -  Patients undergoing emergency surgery (unless full consent is obtained and all
             screening procedures are completed prior to surgery)

          -  Significant concomitant surgical procedure

          -  History of multiple prior laparotomy procedures

          -  Cancer with known metastases pre-operatively, which are suspected to impact
             post-operative recovery or pain

          -  Planned formation of stoma during surgery or plans to undergo another laparotomy
             procedure within 30 days post-operatively

          -  Pre-operative evidence of sepsis or septic shock

          -  Pre-operative evaluation that suggests a surgery may preclude full closure of the
             incision(s)

          -  Patients with current or regular use of systemic steroids, anticonvulsants,
             antiepileptics, antidepressants, or monoamine oxidase inhibitors, who cannot be
             withdrawn from these medications

          -  Patients with current or regular use of drugs known to significantly prolong the QTc
             interval

          -  Patients with known hypersensitivity to local anesthetic agents of the amide type
             (e.g. lidocaine, bupivacaine)

          -  Patients with known hypersensitivity to morphine

          -  Patients with conditions contraindicated for use of opioids

          -  Patients with atrial fibrillation/flutter or other non-sinus rhythm (including paced
             rhythm); left bundle branch block (LBBB); or the following conditions: right bundle
             branch block (RBBB) in presence of a cardiac disease, significant cardiomyopathy, and
             myocardial infarction within last 6 months

          -  Patients with a serum creatinine level two times more than the local laboratory normal
             limit

          -  Patients who have received greater than 600 mg morphine equivalent daily dose for
             three or more days per week in the month prior to the surgical procedure

          -  Patients who are currently being treated with methadone, or history of methadone use
             within the previous 6 months

          -  Patients with known or suspected abuse of opioids or other illicit drugs

          -  Patients with known or suspected alcohol abuse

          -  Participation in another clinical trial at the same time or within 30 days of this
             trial

          -  Patients who, in the Investigator's opinion, should not participate in the trial or
             may not be capable of following the trial schedule for any reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dmitri Lissin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Durect</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DURECT Study Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DURECT Study Site</name>
      <address>
        <city>Florence</city>
        <state>Alabama</state>
        <zip>35630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DURECT Study Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DURECT Study Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DURECT Study Site</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DURECT Study Site</name>
      <address>
        <city>Sheffield</city>
        <state>Alabama</state>
        <zip>35660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DURECT Study Site</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DURECT Study Site</name>
      <address>
        <city>Fontana</city>
        <state>California</state>
        <zip>92335</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DURECT Study Site</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DURECT Study Site</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DURECT Study Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DURECT Study Site</name>
      <address>
        <city>Powder Springs</city>
        <state>Georgia</state>
        <zip>30127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DURECT Study Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DURECT Study Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DURECT Study Site</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DURECT Study Site</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DURECT Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DURECT Study Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DURECT Study Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DURECT Study Site</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DURECT Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DURECT Study Site</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DURECT Study Site</name>
      <address>
        <city>Woodville South</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DURECT Study Site</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DURECT Study Site</name>
      <address>
        <city>Ringwood East</city>
        <state>Victoria</state>
        <zip>3135</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DURECT Study Site</name>
      <address>
        <city>Christchurch</city>
        <zip>8022</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2010</study_first_submitted>
  <study_first_submitted_qc>January 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2010</study_first_posted>
  <disposition_first_submitted>December 20, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>December 20, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 22, 2011</disposition_first_posted>
  <last_update_submitted>December 20, 2011</last_update_submitted>
  <last_update_submitted_qc>December 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postoperative pain</keyword>
  <keyword>Post-operative pain</keyword>
  <keyword>Opioid</keyword>
  <keyword>Laparoscopic surgery</keyword>
  <keyword>Bupivacaine</keyword>
  <keyword>Local anesthetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

